These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 26573958)

  • 1. The dipeptidyl peptidase-4 inhibitor sitagliptin suppresses mouse colon tumorigenesis in type 2 diabetic mice.
    Yorifuji N; Inoue T; Iguchi M; Fujiwara K; Kakimoto K; Nouda S; Okada T; Kawakami K; Abe Y; Takeuchi T; Higuchi K
    Oncol Rep; 2016 Feb; 35(2):676-82. PubMed ID: 26573958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
    Moritoh Y; Takeuchi K; Hazama M
    J Pharmacol Exp Ther; 2009 May; 329(2):669-76. PubMed ID: 19208898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice.
    Schürmann C; Linke A; Engelmann-Pilger K; Steinmetz C; Mark M; Pfeilschifter J; Klein T; Frank S
    J Pharmacol Exp Ther; 2012 Jul; 342(1):71-80. PubMed ID: 22493041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, suppresses CXCL5 and SDF-1 and does not accelerate intestinal neoplasia formation in
    Fujiwara K; Inoue T; Henmi Y; Hirata Y; Naka Y; Hara A; Kakimoto K; Nouda S; Okada T; Kawakami K; Takeuchi T; Higuchi K
    Oncol Lett; 2017 Oct; 14(4):4355-4360. PubMed ID: 28943949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
    Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
    Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of a TGR5 agonist and a dipeptidyl peptidase IV inhibitor on dextran sulfate sodium-induced colitis in mice.
    Sakanaka T; Inoue T; Yorifuji N; Iguchi M; Fujiwara K; Narabayashi K; Kakimoto K; Nouda S; Okada T; Kuramoto T; Ishida K; Abe Y; Takeuchi T; Umegaki E; Akiba Y; Kaunitz JD; Higuchi K
    J Gastroenterol Hepatol; 2015 Mar; 30 Suppl 1(Suppl 1):60-5. PubMed ID: 25827806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice.
    Kim SJ; Nian C; Doudet DJ; McIntosh CH
    Diabetes; 2008 May; 57(5):1331-9. PubMed ID: 18299314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipeptidyl peptidase-4 inhibitor decreases abdominal aortic aneurysm formation through GLP-1-dependent monocytic activity in mice.
    Lu HY; Huang CY; Shih CM; Chang WH; Tsai CS; Lin FY; Shih CC
    PLoS One; 2015; 10(4):e0121077. PubMed ID: 25876091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, attenuates apoptosis of vascular smooth muscle cells and reduces atherosclerosis in diabetic apolipoprotein E-deficient mice.
    Li B; Luo YR; Zhang Q; Fu SH; Chen YD; Tian JW; Guo Y
    Vascul Pharmacol; 2021 Oct; 140():106854. PubMed ID: 33781961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment with Sitagliptin, a dipeptidyl peptidase-4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced rats.
    Femia AP; Raimondi L; Maglieri G; Lodovici M; Mannucci E; Caderni G
    Int J Cancer; 2013 Nov; 133(10):2498-503. PubMed ID: 23649733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the Effects of Mitiglinide and Glibenclamide Administered in Combination with the Dipeptidyl Peptidase-IV Inhibitor Sitagliptin in Rats with Streptozotocin-Nicotinamide-Induced Type 2 Diabetes.
    Akahane K; Ojima K; Yokoyama A; Inoue T; Kiguchi S; Tatemichi S; Takeda H; Kobayashi M
    Drug Res (Stuttg); 2017 Jul; 67(7):396-403. PubMed ID: 28486736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes.
    Hernández C; Bogdanov P; Solà-Adell C; Sampedro J; Valeri M; Genís X; Simó-Servat O; García-Ramírez M; Simó R
    Diabetologia; 2017 Nov; 60(11):2285-2298. PubMed ID: 28779212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sitagliptin alleviated myocardial remodeling of the left ventricle and improved cardiac diastolic dysfunction in diabetic rats.
    Liu YS; Huang ZW; Wang L; Liu XX; Wang YM; Zhang Y; Zhang M
    J Pharmacol Sci; 2015 Mar; 127(3):260-74. PubMed ID: 25837922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
    Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
    Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
    Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H
    Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of dipeptidyl peptidase-4 (DPP-4) inhibition on angiogenesis and hypoxic injury in type 2 diabetes.
    Fiordaliso F; Maggioni S; Balconi G; Schiarea S; Corbelli A; De Luigi A; Figliuzzi M; Antoniou X; Chiabrando C; Masson S; Cervo L; Latini R
    Life Sci; 2016 Jun; 154():87-95. PubMed ID: 27040669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical role of renal dipeptidyl peptidase-4 in ameliorating kidney injury induced by saxagliptin in Dahl salt-sensitive hypertensive rats.
    Sakai M; Uchii M; Myojo K; Kitayama T; Kunori S
    Eur J Pharmacol; 2015 Aug; 761():109-15. PubMed ID: 25936515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34⁺CXCR4⁺ cells in patients with type 2 diabetes.
    Aso Y; Jojima T; Iijima T; Suzuki K; Terasawa T; Fukushima M; Momobayashi A; Hara K; Takebayashi K; Kasai K; Inukai T
    Endocrine; 2015 Dec; 50(3):659-64. PubMed ID: 26209038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DPP-4 Inhibition Leads to Decreased Pancreatic Inflammatory Profile and Increased Frequency of Regulatory T Cells in Experimental Type 1 Diabetes.
    Davanso MR; Caliari-Oliveira C; Couri CEB; Covas DT; de Oliveira Leal AM; Voltarelli JC; Malmegrim KCR; Yaochite JNU
    Inflammation; 2019 Apr; 42(2):449-462. PubMed ID: 30707388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dipeptidyl peptidase-4 inhibitor promotes wound healing in normoglycemic mice by modulating keratinocyte activity.
    Shih CM; Huang CY; Huang CY; Wang KH; Wei PL; Chang YJ; Fong TH; Pan JL; Lee AW
    Exp Dermatol; 2018 Oct; 27(10):1134-1141. PubMed ID: 30028901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.